Gravity Analytica

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

FENC 10.31.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-07

Name of Upcoming Event:N/A

Full Press Release SEC Filings Our FENC Tweets

About Gravity Analytica

Recent Filings

RESEARCH TRIANGLE PARK, N.C.,Oct. 31, 2024(GLOBE NEWSWIRE) --Fennec Pharmaceuticals Inc.(NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of theU.S.financial markets onThursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results.

Conference Call & Webcast Detail:

Date:	Thursday, November 7, 2024
Time:	8:30 a.m. Eastern Time
Link:	https://edge.media-server.com/mmc/p/e6my278s

To access the conference call, please register usinghttps://edge.media-server.com/mmc/p/e6my278s. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log ontowww.fennecpharma.comand proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived onwww.fennecpharma.comfor thirty days.

About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visitwww.fennecpharma.com.

For further information, please contact:

Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299

Corporate and Media:Lindsay RoccoElixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Source: Fennec Pharmaceuticals Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com